

## Anaesthesia recommendations for patients suffering from

### **McArdle Disease**

**Disease name:** McArdle Disease

**ICD 10:** ICD 10 E74.04

**Synonyms:** Glycogen storage disease type 5, GSD type 5, GSDV, Glycogenosis type V, Myophosphorylase deficiency, McArdle Disease, Muscle Glycogen Phosphorylase Deficiency

McArdle Disease (GSD V) is a rare skeletal myopathy secondary to a disorder of carbohydrate metabolism. It is an autosomal recessive condition with an incidence of approximately 1 in 100,000 and is caused by the absence of muscle glycogen phosphorylase (myophosphorylase). Clinical features include exercise intolerance which consists of acute crisis of early fatigue and muscle stiffness and contractures, especially at the start of the exercise, that usually disappear if exercise is stopped or the intensity is reduced. These episodes are sometimes accompanied by rhabdomyolysis and myoglobinuria (dark urine).

---

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong

---



**Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)**

## Disease summary

---

GSD V was described in 1951 by Brian McArdle.

GSD V is caused by pathogenic mutations in the *Pygm* gene (chromosome 11q13) which encodes the muscle glycogen phosphorylase enzyme (GP-M) (myophosphorylase). It is an autosomal recessive disorder with an estimated prevalence of 1/100000 with both sexes similarly affected. GP-M catalyzes and regulates the breakdown of glycogen into glucose-1-phosphate in muscle fibers[1]. Almost all patients have no detectable myophosphorylase activity, thus they are unable to obtain energy from their muscle glycogen stores and, as a result, commonly experience exercise intolerance. [2] A positive family history can be identified in 50% of patients [3], and the most common mutation in the *Pygm* gene in Caucasians is the p.R50X.[4]

The majority (50%) of patients are identified between the ages of 10-30 years with less than 4% of cases diagnosed before 10 years. The true incidence of the disease is unknown due to the benign character of the disease and the resulting missed or late diagnosis.

The diagnosis is based on clinical findings, and supportive laboratory findings of a low or absent myophosphorylase activity on histochemical or biochemical examination of a muscle biopsy and subsequent genetic testing. The absence of increased lactate during exercise and a raised creatine kinase are also features. [5]

Although no specific treatment for the enzyme deficiency is available, affected individuals benefit from a number of therapeutic options which have been shown to reduce symptoms or to enhance the ability for physical activity, moderate aerobic training to increase cardiorespiratory fitness and muscle oxidative capacity.[5] Pre-exercise ingestion of sports drinks containing simple carbohydrates improves exercise tolerance and may protect against exercise-induced rhabdomyolysis.[6] There are a number of case reports suggesting a benefit with beta-2-sympathomimetics, vitamin B6 and coenzyme Q10. [7-8] However, Phoenix et al, reported no significant beneficial effects with Vitamin B6. [9] The best intervention you can do for McArdle patients is appropriate exercise habits. For example, after gradual, supervised training, a 38-year-old patient (with no myophosphorylase activity) could run regularly and cover 10 km in \*60 min with no rhabdomyolysis. The average time for recreational runners to complete a 10 km race generally falls between 75–80 min.

The prognosis is good. Fixed muscle weakness occurs in approximately 25% of affected individuals, is more likely to involve proximal muscles, and is more common in individuals of advanced age.8 There are a small number of case reports of generalised weakness after birth with death occurring in childhood.[8] There are no reports of limitations of life due to cardio-circulatory disease. 50% of affected individuals have recurrent episodes of myoglobinuria, and acute renal failure in 27% of patients after strenuous exercise. [2] Patients do need to learn how to cope with the disease and how to avoid major muscle damage, which can result in acute rhabdomyolysis and renal failure.

## Typical surgery

---

There is no typical surgery, unlike in patients suffering from other glycogen storage disorders.

---

## **Type of anaesthesia**

---

Anaesthesia for individuals with GSD V should be undertaken with care and precaution. There is weak support in the scientific literature for a connection between GSD V and MH. Until it has been proven that a positive in-vitro contracture test in GSD V is nonspecific and there is no risk of MH, all patients with GSD V may be at risk of developing MH or MH like syndromes. It remains wise to avoid MH trigger substances as far as possible. [10]

In principle all types of anaesthesia can be used (i.e. regional and general as well as a combination of both). Preference is given to local or regional techniques but if general anaesthesia is performed, all MH trigger substances must be strictly avoided.

- Depolarizing muscle relaxants of type succinylcholine
- All volatile anaesthetics including halothane, enflurane, isoflurane, sevoflurane and desflurane

---

## **Necessary additional diagnostic procedures (preoperative)**

---

Prior to planned surgery creatine kinase, lactate dehydrogenase, transaminases, creatinine should be taken and monitored post operatively for 24-hours.

Routine bloods such as a full blood count, coagulation studies, blood chemistry and blood crossmatch should be taken when indicated and according to the standard requirements of the surgical procedure.

Diagnostic investigations for patients under investigation for GSD V include: routine biochemistry including serum CK (creatinine kinase), urate, carnitine and acyl carnitine. Screening DNA blood test to look for hot spot mutations. Electromyography (EMG) for patients for whom the diagnosis is not confirmed to rule out other disorders and muscle and skin biopsy.

---

## **Particular preparation for airway management**

---

A difficult airway is not a classic feature of GSD V.

---

## **Particular preparation for transfusion or administration of blood products**

---

Standard management.

---

## **Particular preparation for anticoagulation**

---

Standard management.

## **Particular precautions for positioning, transport or mobilisation**

---

Tourniquets should be avoided in GSD V as they can cause muscle damage.[12]

## **Probable interaction between anaesthetic agents and patient's long term medication**

---

Standard management.

## **Anaesthesiologic procedure**

---

Children with GSD V should be anaesthetised after a thorough perioperative assessment, careful consideration as to the necessity of the surgical procedure and a frank discussion with the family regarding the risks of anaesthesia and the options available to them.

In general, patients with GSD V are at risk of developing specific perioperative complications; hypoglycaemia, rhabdomyolysis, myoglobinuria, acute renal failure, post-operative fatigue and possibly malignant hyperthermia (MH). Identification of patients at risk for malignant hyperthermia is the first step for safe perioperative management. Patients reporting an MH event or complications during anaesthesia should be referred to an MH Investigation Centre for further diagnosis if possible. For safety reasons, patients who decline MH testing should be treated as though at risk.

Management of the glycogen storage diseases involves maintaining an adequate blood glucose level and supplementing the muscle with alternate energy sources. In infants this usually involves regular daytime snacking and nocturnal intragastric glucose feeds or uncooked cornstarch in older children.

The anaesthesia machine must be flushed free of volatile anaesthetics prior to anaesthesia, as recommended in the guidelines from the European MH Group (EMHG) and the MH Association of the United States (MHAUS). All parts of the anaesthesia machine that might have been in contact with volatile anaesthetics must be exchanged and the gas circuit washed with a fresh gas flow of 10l/min for at least 10 minutes. Newer anaesthetic workstations may require significantly more time for purging the machine. The use of an in line charcoal filter apparatus will also reduce volatile gas concentration to very low levels.

The vaporizer should be removed from the anaesthetic machine in order to avoid an accidental administration of volatile anaesthetics. Nitrous oxide is safe in patients who are thought to be susceptible of MH. In susceptible pigs, Xenon administration did not trigger MH, however, studies in humans are lacking.

Premedication can be administered as usual (i.e. benzodiazepines), but prophylactic administration of dantrolene is obsolete. Intravenous anaesthetic agents, such as barbituates, propofol, etomidate are safe to use both for induction and maintenance of anaesthesia. All opioids are safe for use including morphine, remifentanyl, alfentanil, fentanyl.

Avoid suxamethonium in all patients with myopathy due to the risk of hyperkalaemia and MH.

Dantrolene must be immediately available in the unlikely event of MH.

Termination of anaesthesia should be carried out in a routine environment. Administration of antagonists such as neostigmine or naloxone is possible, if required.

---

### **Particular or additional monitoring**

---

Standard monitoring of vital signs should be performed in all types of anaesthesia including sedation. Monitoring should follow the usual standard and at least comprise ECG, blood pressure, pulse oximetry and continuous measurement of body temperature as well as capnography in ventilated patients.

---

### **Possible complications**

---

Patients are at risk of MH if trigger substances are administered. Therefore all trigger substances must be strictly avoided.

MH is characterized by hypermetabolism due to overflowing of the myoplasm with calcium. Clinical signs include; Tachycardia hypercapnia, hypoxaemia, muscle rigidity and masseter muscle spasm, hyperthermia, rhabdomyolysis and metabolic as well as respiratory acidosis

Hypermetabolism induced disturbances of permeability in skeletal muscle cells may cause elevated  $Ca^{2+}$  and  $K^+$  levels, which may lead to severe cardiac arrhythmias. Blood analyses might reveal elevated concentrations of creatine phosphokinase (CK) although CK levels only start to increase 2 – 4 hours after the onset of MH, reaching a maximum after 24 – 36 hours. In case of severe injury of skeletal muscle cells, myoglobin can be detected in blood and urine. Delayed therapeutic intervention may be lethal resulting in bradycardia or cardiac arrest.

Rhabdomyolysis and myoglobinuria may lead to acute renal failure.

---

### **Postoperative care**

---

Standard ward post operative care but consider 24-hour postoperative supervision in an intensive care unit if there are any concerns. [10]

---

### **Information about emergency-like situations / Differential diagnostics**

---

In the event of cardiac and/or respiratory compromise or arrest, standard national paediatric resuscitation guidelines should apply to children with GSD V.

---

### **Ambulatory anaesthesia**

---

Standard guidelines.

---

### **Obstetrical anaesthesia**

---

As patients with GSD V have a normal fertility, pregnancies are possible and described. A prenatal diagnosis is possible. For delivery, caesarian sections and vaginal delivery are possible. Regional anaesthesia is recommended. [13-15]

## Literature and internet links

1. What is McArdle Disease? <http://mcardledisease.org> Accessed November 3, 2016
2. DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C, eds. *Myology*. New York:McGraw-Hill1994;1554-1576
3. Kubisch C, Wicklein EM, Jentsch TJ. Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation. *Hum Mut* 1998; 12:27-32
4. Di Mauro S. Muscle glycogenoses: an overview. *Acta Myologica* 2007;XXVI:35-41
5. Bartram C, Edwards RHT, Beynon RJ. McArdle's disease-muscle glycogen phosphorylase deficiency. *Biochi Biophys Acta* 1995;1272:1.13
6. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. *N Engl J Med* 2003;349:2503-2509
7. Pernow BB, Havel RJ, Jennings DB. The second wind phenomenon in McArdle's disease. *Acta Med Scand* 1967;472:294-307
8. Bollig G. Das McArdle-Syndrom (Glykogenose Typ 5) Unter Sportmedizinische Gesichtspunkten. Koeln: Inaugural-Dissertation Universitat zu Koeln 2000
9. Phoneix J, Hopkins P, Bartram C, et al. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. *Neuromuscul Disord*. 1998;8(3-4):210-2
10. Davis PJ, Brandom BW. The Association of Malignant Hyperthermia and Unusual Disease: when You're Hot You're Hot, or Maybe Not. *Anesth Analg* 2009;109:1001-1003
11. Bollig G. McArdle's disease (glycogen storage disease type V) and anaesthesia – a case report and review of the literature. *Paed Anaes* 2013;817-823
12. Baum VC, O'Flaherty JE, *Anesthesia for Genetic, Metabolic and Dysmorphic Syndromes of Childhood*, Second Edition, Lippincott Williams and Wilkins 2006
13. Bollig G. McArdle's disease (glycogen storage disease type V) and anaesthesia-a case report and review of the literature. *Paediatr Anaesth*. 2013 Sep;23(9):817-23
14. Obstetric Reference – Coleman P. McArdle's Disease. Problems of anaesthetic management for Caesarean section. *Anaesthesia* 1984;39:784-7
15. Obs reference Gambling DR, Douglas JM, McKay RS. *Obstetric Anesthesia and Uncommon Disorders*. 2<sup>nd</sup> ed. New York, NY: Cambridge University Press; 2008:239-240
16. Yokoi A, Iwakura H, Fujimoto K. Anesthesia in a Patient with McArdle Disease. *Masui*. 2015 Nov;64(11):1203-5.

---

**Last date of modification: December 2017**

---

*This guideline has been prepared by:*

**Authors**

**Mae Johnson**, Department of Anaesthesia, Great Ormond Street Hospital, London, United Kingdom

[Mae.Johnson@gosh.nhs.uk](mailto:Mae.Johnson@gosh.nhs.uk)

**Grant Stuart**, Paediatric Anaesthetic Consultant, Department of Anaesthesia, Great Ormond Street Hospital, London, United Kingdom

**Peer revision 1**

**Mark A. Tarnopolsky**, Professor of Pediatrics and Medicine, CEO and CSO, Exerkine Corporation, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center, Ontario, Canada

[tarnopol@mcmaster.ca](mailto:tarnopol@mcmaster.ca)

**Peer revision 2**

**Tomàs Pinos Figueras**, Departament de Patologia Mitocondrial i Neuromuscular, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Spain

[tomas.pinos@vhir.org](mailto:tomas.pinos@vhir.org)

*Please note that this guideline has been reviewed by two anaesthesiologists, but by two disease experts instead.*

---